ReviewFrontiers in cardiovascular medicine2024
Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome.
Review in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of colchicine for secondary prevention of cardiovascular diseases in individuals with diabetes: A meta-analysis of randomized trials.Diabetes & vascular disease researchPooled it
- The Cardio-Onco-Immune Axis: immunopathological mechanisms in the cardiac microenvironment of checkpoint inhibitor-induced myocarditis.Acta pharmacologica Sinica · 2026Review
- Inflammation and Immune Mediators in the Context of Atherosclerotic Cardiovascular Disease and Percutaneous Coronary Intervention: Implications for Therapeutics.Medical sciences (Basel, Switzerland) · 2026Review
- Prognostic Value of the Osaka Prognostic Score for One-Year Mortality in Patients with ST-Segment Elevation Myocardial Infarction: A Retrospective Observational Cohort Study.Journal of clinical medicine · 2026Article
- Left Ventricular and Left Atrial Strain Characteristics in Patients with Familial Mediterranean Fever Receiving Long-Term Colchicine Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Machine learning-derived identification of an obesity and lipid metabolism-related genes signature for the diagnosis and molecular typing of acute myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes.Journal of clinical medicine · 2025Review
- Role of anti-inflammatory agent colchicine in atherosclerotic cardiovascular disease.World journal of clinical cases · 2025Review
- TG/HDL-C Ratio as a Superior Diagnostic Biomarker for Coronary Plaque Burden in First-Time Acute Coronary Syndrome.Diagnostics (Basel, Switzerland) · 2025Article
- Relationship Between Systemic Immune-Inflammation Index and In-Hospital Mortality in Sepsis Combined With Chronic Obstructive Pulmonary Disease Modified by Mechanical Ventilation.The clinical respiratory journal · 2025Article
- The Importance of Hemostasis on Long-Term Cardiovascular Outcomes in STEMI Patients-A Prospective Pilot Study.Journal of clinical medicine · 2025Article
- Anti-inflammatory interventions in coronary artery disease: antipodal responses requiring targeted therapeutic strategies.Basic research in cardiology · 2025Review
- Clonal Hematopoiesis of Intermediate Potential in Atrial Fibrillation: A Critical View of Current Knowledge as a Springboard for Future Research.Diagnostics (Basel, Switzerland) · 2025Review
- The Crosstalk Between NETs and the Complement Cascade: An Overview in Nephrological Autoimmune Disease.International journal of molecular sciences · 2025Review
- Prognostic Role of Inflammatory Hematologic Indices in Predicting Acute Coronary Syndrome in Elderly Patients with Chronic Coronary Syndrome.Journal of inflammation research · 2025Article
- Role of Macrophage Phagocytosis as Predictive Marker of the Prevalence of Coronary Heart Disease and Acute Coronary Syndromes.Cardiovascular therapeutics · 2025Article
- Connecting the Dots: FGF21 as a Potential Link between Obesity and Cardiovascular Health in Acute Coronary Syndrome Patients.Current issues in molecular biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Coronary Syndrome (ACS) significantly contributes to cardiovascular death worldwide. ACS may arise from the disruption of an atherosclerotic plaque, ultimately leading to acute ischemia and myocardial infarction. In the pathogenesis of atherosclerosis, inflammation assumes a pivotal role, not solely in the initiation and complications of atherosclerotic plaque formation, but also in the myocardial response to ischemic insult. Acute inflammatory processes, coupled with time to reperfusion, orchestrate ischemic and reperfusion injuries, dictating infarct magnitude and acute left ventricular (LV) remodeling. Conversely, chronic inflammation, alongside neurohumoral activation, governs persistent LV remodeling. The interplay between chronic LV remodeling and recurrent ischemic episodes delineates the progression of the disease toward heart failure and cardiovascular death. Colchicine exerts anti-inflammatory properties affecting both the myocardium and atherosclerotic plaque by modulating the activity of monocyte/macrophages, neutrophils, and platelets. This modulation can potentially result in a more favorable LV remodeling and forestalls the recurrence of ACS. This narrative review aims to delineate the role of inflammation across the different phases of ACS pathophysiology and describe the mechanistic underpinnings of colchicine, exploring its purported role in modulating each of these stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.